
Ghana is set to establish two specialized pharmaceutical and biomanufacturing hubs in the Eastern and Central regions by 2027, backed by a $1 billion investment compact. This initiative represents a strategic shift toward domestic self-reliance, aiming to elevate the local production of essential medicines to a target share of 60% to 80% by 2030. By reducing the current heavy dependence on imported healthcare products, the government intends to secure the national supply chain and establish Ghana as a primary manufacturing center for the West African sub-region.
The project, designated as a Presidential National Legacy Flagship, will provide state-of-the-art infrastructure designed to accommodate both domestic and international pharmaceutical firms. These hubs are expected to facilitate a wide range of activities, including contract manufacturing, high-level research and development (R&D), and the large-scale production of vital health commodities. Dr. Bernice Makafui Brempong noted that the initiative has the potential to retain pharmaceutical expenditure within the country, fostering economic growth while ensuring that essential drugs are more readily available to the populace.
Experts have underscored that the success of these ambitious healthcare reforms will rely heavily on the quality of human capital. Dr. Martha Gyansa-Lutterodt pointed out that a competent and well-trained pharmaceutical workforce is essential to drive the innovation and operational efficiency required for such large-scale biomanufacturing hubs. This focus on workforce development is seen as a critical pillar in supporting the broader healthcare infrastructure improvements planned under the investment compact.
Ultimately, the establishment of these hubs is expected to create a more resilient healthcare system capable of withstanding global market fluctuations. By fostering a centralized ecosystem for medicine production, Ghana aims not only to meet its internal health needs but also to emerge as a competitive exporter of pharmaceutical products to neighboring African nations. This $1 billion commitment signals a long-term strategy to integrate industrial manufacturing with public health priorities, ensuring sustainable access to affordable medicine for all citizens.